Notably, several targeted agents have shown efficacy in patients with leptomeningeal disease, including lorlatinib and alectinib for ALK-positive cancers and selpercatinib in RET-fusion NSCLC [80,81]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.